Serum Sialic Acid in Normals and in Cancer Patients by Shamberger, R. J.
Shamberger: Serum sialic acid in normals and in canccr paticnts 647
J. Clin. Chcm. Clin. Biochem.
Vol. 22, 1984, pp. 647-651
Serum Sialic Acid in Normals and in Cancer Patients
By R. y. Shamberger
The Cleveland Clinic Foundation, Department of Biochemistry, Cleveland, Ohio, USA
(Received January 19/July 5, 1984)
Summary: A simple procedure is described for the detection of sialic acid in serum. After a direct addition of
Ehrlich reagent to serum and an incubation at 56 °C for eight hours, the resulting mixture is diluted with
saline. After centrifugation, the color in the supernatant is determined at 525 nm in a spectrophotometer.
Serum sialic acid was significantly greater in cancer patients than in normals. Cancer patients with metastases
had significantly greater sialic acid than cancer patients without metastases. In two cancer patients, sialic acid
levels returned to normal after surgery. The diagnostic usefulness of 95.6% was similar to that reported with
lipid-soluble sialic acid and seemed to be superior to CEA and other tumor antigens associated with a limited
spectrum of tumors. However, patients with inflammatory diseases such äs arthritis, Crohn's disease and
psoriasis also showed elevated sialic acid levels.
Ultrafiltration showed that almost all of the sialic acid was retained on an Amicon filter, which suggests that
sialic acid was bound to a macromolecule. A quality control serum run 25 times had a coefficient of Variation
(CV) of 8.4% arid the same serum ran on 42 days had a CV of 11.6%.
Sialinsäure im Serum von Gesunden und Patienten mit Carcinomen
Zusammenfassung: Ein einfaches Verfahren zum Nachweis von Sialinsäure im Serum wird beschrieben. Nach
Zugabe von Ehrlichs Reagenz direkt zum Serum und Inkubation für 8 Stunden bei 56 °C wird das Gemisch
mit physiologischer NaCl-Lösung verdünnt. Nach Zentrifugation wird die Farbintensität des Überstandes bei
525 nm in einem Spektralphotometer bestimmt. Die Sialinsäurekonzeritration war im Serum von Carcinom-
patienten signifikant höher als im Serum von Gesunden. Sie war bei Patienten mit Metastasen höher als bei
denen ohne Metastasen. Bei zwei Patienten fiel die Sialinsäurekonzentration nach Operation auf bei Ge-
sunden gefundene Werte ab. Der diagnostische Wert der Ergebnisse dieses Bestimmungsverfahrens von
95,6% ist vergleichbar mit dem für lipidlösliche Sialinsäure berichteten und scheint den von carcinoembryo-
nalem Antigen und anderen Tumorantigenen, die bei einem begrenzten Spektrum von Tumoren vorkommen,
zu übertreffen; jedoch zeigten auch Patienten mit entzündlichen Erkrankungen wie Arthritis, Morbus Crohn
und Psoriasis erhöhte Sialinsäurekonzentrationen.
Ultrafiltration zeigte, daß fast die gesamte Sialinsäure an Amicon-Filtern zurückgehalten wurde, weil Sialin-
säure wahrscheinlich an ein Makromolekül gebunden ist. Der Variationskoeffizient in der Serie (N = 25)
wurde mit einem Qualitätskontrollserum zu 8,4% ermittelt. Er betrug mit dem selben Serum von Serie zu
Serie (N = 42) 11,6%.
animals and humans bearing metastasizing tumors
Introduction (3-6).'Serum sialyltransferase and 5'-nucleotidase
Several glycosyltransferase levels have been report- were found to be reliable biomarkers of breast
ed to be abnormal in human cancer (l, 2). The cata^ cancer activity, and serial measurements of these en-
lytic concentrations of one enzyme, sialyltransferase zyme activities were used for the monitoring of dis-
were found to be elevated in sera obtained for both ease activity and success or failure of the treatment
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(7). Serum sialic acid and sialyltransferase have also
been used to monitor tumor b rden in malignant
melanoma patients (8), but sialic acid levels ap-
peared to more closely reflect tumor b rden than si-
alyltransferase activity. Lipid-bound sialic acid and
sialic acid have also been observed to be significantly
elevated in cancer patients (9). In other studies, lip-
id-bound sialic acid was also found to be elevated in
cancer patients (10, 11).
The methods associated with sialyltransferase mea-
surement, lipid associated sialic acid, and sialic acid
are somewhat complex for clinical laboratories. The
objective of these experiments is to try to find a less
complex way to measure serum sialic acid. In these
experiments, Ehrliches reagent is added directly to
serum and after a long incubation, the mixture is dil-
uted, centrifuged, and read directly on a spectropho-
tometer. This method was used to measure sialic acid
in the sera of patients with cancer and other diseases.
Material and Method
Sera s t u d i e d
Siaiic acid level was measured in the sera from 134 normal males
and females and 160 cancer patients of which 63 had known me-
tastases. All cancer patients were verified by a biopsy, or patho-
logical examination of their cancer after surgery. The following
are the types of cancers and number of patients studied: breast
(11); rectal (14); uterine (23); leukemias and lymphomas (21);
pancreatic (4); lung (14); larynx (9); colon (8); ovarian (5); testis
(3); Hodgkitfs disease (4); renal (3); bladder (3); esophageal (4);
melanoma (7); prostate (4); and 23 patients with several other
types of cancer; (4) with sarcomas, and cancer, and (5) with brain
tumors. Sialic acid level was also measured in several patients with
various types of inflammatory disease: arthritis (42), psoriasis
(14) CIO/I/I's disease (13), and ulcer (3).
S i a l i c Acid Assay
Water (0.5 ml) was added to 0.5 ml serum. Blank tubes contained
l ml of water. At that time, 0.2 ml of Ehrlich solution was added
and the solution was vortexed. Ehrliches reagent is made by ad-
ding 0.7 g of/7-dimethylaminobenzaldehyde to 150 ml of concen-
trated HC1 and 100ml of distilled water. Ehrlich'* reagent has
been previously used to measure sialic acid (12).
A white precipitate forms immediately. The tube was covered
with parafilm and its Contents were then incubated in a 56 °C wa-
ter bath for 8 hours. The tubes were agitated gently at l, 3, 5 and
7 hours. The Contents of the tubes gradually turned blue in the
eight hour incubation period. At the conclusion of the incubation,
3.0 ml of 9 g/l NaCl solution are added to each tube and they were
centrifuged at 2500g for 15 minutes. The supernatant was re-
moved but sometimes contained some precipitate because of mix-
ing during supernatant removal. The supernatant was recentri-
fuged at 2500g for 15 minutes and then placed in a cuvet, which
was read in a Pye-Unicam spectrophotometer at 525 nm. The co-
lor was quite stable and could be read 16 hours later with no sub-
stantial difference in the absorbance. In two recovery studies in
which 5 and 10 μιποί were added to 1.8 μιηοΐ in l ml of serum, the
amounts recovered were 6.7 μπιοί (98.5%) and 11.5 μηιοί
(97.5%). Although there is no established reference method for
sialic acid, one serum was run ten times by this method and the
periodate oxidation-thiobarbituric acid-cyclohexanone method
(8). The results by this method wcrc 1.90 ± 0.13 and 1.85 ±0.15
mmol/1 by the other method. Ehrfich's reagent is also known to
react with urobilinogen, but this complex has an absorption maxi-
mum at 562 nm. The good recovery experienced seems to indicate
that the method is sufficiently specific.
The assay was at least linear to an absorbance of 0.630 corre-
sponding to 0.59 mmol/l serum. The serum could be diluted l :2
or l :4 with proportional changes in the bsorbance. Grossly he-
molyzed samples, icteric samples, and lipemic samples changed
appearance during the long incubation. After the incubation and
centrifugation, the supernatant from lipemic and icteric samples
could not be visually identified among the other samples. Grossly
hemolyzed samples, after incubation, appeared to have a browner
precipitate, but had no visible difference in the supernatant.
Chemistry control serum 1-Highland Q-pak was used s a quality
control sample. This quality control sample was run 42 times on a
day-to-day basis and in another experirnerit, 25 samples were run.
CEA (Hoffmann LaRoche) levels were compared to sialic acid
levels in 10 cancer patients and in two normals.
Sialic acid levels were recorded before and for four days after
surgery in a 47-year-oId ferriale with breast cancer and in a 57-
year-old male with colon cancer. After searching the medical fe-
cords it was observed that 53 patients had died from cancer or
cancer-related complications. To test whether sialic acid levels
might be related to the severity of the disease, sialic acid levels
were compared to the time of death in these patients. In another
experiment to determine the amount of free and bound sialic acid
in serum, serum was passed through an Amicon filter Centriflo
Ultrafiltration Membrane Cones, CF-50A which is routifiely used
to measure ultrafilterable calcium. Sialic acid levels wefe deter-
mined on the filtrate.
Results
With the method described above, there was gradual
increase of color until the seventh hour of incubation
when the increase of absorbance seemed to plateau
(fig. 1). In contrast, stan^ajd sialic acid reached
rhaximum color action in 45 minutes. Apparently si-
alic acid was gradually released from some macro^
molecule in the serum. Ultrafiltration showed that
almost all of the sialic acid was retained on the filter
indicating that sialic acid was bound to a rhacrom le-
cule such s glycoprotein.
Patients with breast, rectal, uterine, pancreatic, lung,
laryngeal, colon, ovarian, testicular, bladder, eso-
phageal, and prostatic cancer s well s patients with
melanoma, Hodgkin's disease and leukemia or lym-
phoma had significantly greater sialic acid levels (P
< 0.001) than the controls (tab. 1). Of the 160
cancer patients in table l, 151 (94%) had sialic acid
levels greater than 2 Standard deviations (S.D.) of
the controls. Of the 9 patients wh did not have sialic
acid values greater than the controls, one patient
with uterine cancer and one with rectal cancer had
received radiation treatment either the same day or
the day before blood was drawn. In addition, 4 of 4
sarcoma patients had elevated sialic acid levels. The
'results were: bone sarcoma 2.6,.2/2; and leiomysar-
coma 2.6, 2/2. Brozmanova &tSkrovina (13) have
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Fig. 1. The relationship between the color development of sialic Nasal-pharyngeal




also observed significant elevation of sialic acid
among sarcoma patients compared to normals or pa- * p < °·05























































































































beyond two Standard deviations of normal and the
type of brain tumors studied included: glioblastomas
2.6, 2/3; glioma 1.8, 0/1; and a craniopharyngioma
2.7, l/l. Of the 134 normals, 6 had values greater
than 2 S.D. of the mean and were false positives.
One hundred and thirty-four normals had a serum
sialic acid level of 1.74 ± 0.24 (S.D.) mmol/l where-
as 160 cancer patients had a level of 2.99 ± 0.72 and
63 cancer patients with inetastases had a level of
3.23 ± 0.73. Using a Mest of significance both the
cancer patients and cancer patients with metastases
wefe significantly different than the controls (P <
0.001). With the t test, the sialic acid level in cancer
patients without metastases was also significantly
different thaii the cancer patients with metastases.
The higher sialic aicid levels in the patients with me-
tastases probably represents the greater tumor
b rden and sialic acid production by the cancer pa-
tients.
Figure 2 shows the fiVe day postoperative sialic acid
levels in a 52-year-old man with colon cancer and a
43-year-old woman with breast cancer. After the
Fig. 2. Sialic acid in a 57-year-old male colon cancer patient
(O-O) and a 47-year-old female breast cancer patient
(·-·) before and for five days after surgery.
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cancer was removed the serum sialic acid levels re-
turned to normal. Mrochek et al. (14) have mea-
sured protcin-bound sialic acid levels in women with
breast cancer. They report consistent increases in
those with progressive tumor and consistent de-
creases in levels in patients whose disease is respond-
ing to therapy.
A correlation coefficient of 0.44 (P < 0.01) was ob-
served between sialic acid levels and days before
death for 53 cancer patients (fig. 3), which indicates
a relationship between sialic acid levels and severity
of the disease. Even though one cannot predict the
time of death for an individual patient, a greatly ele-
vated sialic acid is a poor prognostic sign. Patients
(tab. 2) with inflammatory diseases such äs arthritis
(P < 0.001), psoriasis (P < 0.01), Crohn's disease
and with ulcers (P < 0.001) also had significantly
elevated sialic acid levels.
When the diagnostic usefulness of CEA was com-
pared to sialic acid in two normals and ten cancer
patients, (tab. 3), only four of ten patients had an
elevated CEA. In contrast, all 10 cancer patients had
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Fig. 3. The correlation between sialic acid levels and the days be-
fore death in cancer patients. N = 53;r = 0.44; p < 0.01.
Hyland reference serum (Chemistry Control Serum I
Hyland Q-Pak) seemed to be useful äs a quality con-
trol serum for sialic acid with a day-to-day (N = 42)
coefficient of Variation of 11.6% and within run Vari-
ation (N = 25) of 8.4%.
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Methods associated with sialyltransferase measure-
ment, lipid-associated sialic acid, and sialic acid mea-
surement are difficult for routine analysis by clinical
laboratories because eithertadioactive^labetted Sub-
strates, labile reagents, or solvent extractions afe re-
quired. Sialyltransferase assay requires a precipita-
tion of a radioactive Substrate by phosphötungstic
acid precipitation; sialic acid is oxidized with perio-
dic acid and then extracted into cyclohexanone. The
major advantages of the procedure reported here is
that one stable reagent is added to serum and after
incubation in a water bath and centrifugations, the
absorbance is read in a spectrophotometer. All of
this type of equipmerit is pfesent in a clinical labora-
tory. The major disadvantage is the 8-hour. incuba-
tion plus another hour for final analysis. In addition,
the method is known to be less sensitive than the
thiobarbituric method (14). However, the sensitivity
of the method was more than adequate. If micro-
cuvettes were used considerably less than 0.5 ml of
serurn could be used.
Previous studies have iridicated that lipid-boünd sia-
lic acid may be a reliable marker in cancer (15). Of
670 cancer patients, 88% had elevated levels com-
pared with 17% of patients witll· benigft disease and
no normal patients had elevated levels. In another
J. Clin. Chem. Clin. Biochem. / Vol. 22, 1984 / No, 10
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study (8), sialic acid levels correlated with cancer di-
agnosis in 19 of 24 (79%) patients, whereas sialyl-
transferase indicated cancer in 14 of the 24 patients
(58%). Changes in sialyltransferase tended to be less
marked than sialic acid and the interassay Variation
of the enzyme assay decreased the significance of
small changes. The diagnostic usefulness of sialic
acid in this study was quite comparable, with 94%
(151 of 160) of cancer patients showing elevated lev-
els. There were 4.5% (6 of 134) false-positives. A
comparative study between plasma lipid-bound sialic
acid levels and CEA showed that 97/125 (78%)
cancer patients had elevated lipid-soluble sialic acid
(10), but of the satne patients only 44/125 (35%)
had elevated CEA. These numbers are comparable
to the results of this small series of 100% and 40%.
Hogan-Ryan (16) has also observed a higher diag-
nostic efficiency of sialic acid (56%) in breast cancer
patients than CEA (35%). The elevations of serum
sialic acid in arthritics were similar to those reported
by Silver et al. (8), who observed significant eleva-
tions of sialic acid and sialyltransferase in patients
with rheumatoid arthritis. There was a tendency for
both markers to be more elevated in patients with
active arthritis than in patients with inactive arthritis.
The elevations of serum sialic acid may be related to
increases of acute phase reactants. In other studies,
sialic acid levels correlated with the stage of disease
(17—20), tumor bürden (8,21)> degree of metastasis
(20, 22), and recurrence of disease (20). The rapid
postoperative decrease of sialic acid (fig. 2) is in con-
trast to two other studies (23,24). Differences in sia-
lic acid determination or types of cancer patients stu-
died may be responsible for these contrasting stu-
dies.
Unlike tumor antigens, which are associated with a
limited spectrum of tumors, increased sialic acid lev-
els due to sialyltransferase activity and associated si-
alylglycoprotein production appear to be a common
phenomenon of a variety of neoplastic cells. As a re-
sult, relatively nonspecific markers such äs sialic acid
and sialyltransferase or lipid-soluble sialic acid may
have useful clinical applications äs a cancer screen.
The diagnostic effectiveness of sialic acid is better
than that of CEA, one of the leading cancer screen-
ing tests. However, because of the technical prob-
lems involved in measuring sialic acid, sialyltransfe-
rase or lipid-soluble sialic acid, these assays have not
been used widely. This simplified assay should en-
hance acceptance of the test. Even though there are
false positives with arthritics and in patients with
other inflammatory diseases, measurement of sialic
acid is, however, dramatically easier than measure-
ment of other cancer markers. In addition, 5—10%
of false positives of normal patients also occur with
CEA (21, 25). Other types of tests could be done in
conjunction with an elevated sialic acid level to help
with its diagnostic effectiveness.
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